Entremed (ENMD)

[Rocky I]

EntreMed Announces Poster Presentations At ASCO On ENMD-2076




ROCKVILLE, Md., May 19, 2014 - EntreMed, Inc. (Nasdaq: ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of cancer and other diseases, announced today two poster
presentations on ENMD-2076 at the American Society of Clinical
Oncology Annual Meeting for two of its trials currently in progress.
ENMD-2076 is currently in Phase 2 advanced soft tissue sarcoma and
Phase 2 ovarian clear cell carcinoma, trials at Princess Margaret
Cancer Centre in Toronto. ASCO will be held May 30 – June 3, 2014
in Chicago, IL. The posters will be presented during separate poster
sessions listed below and will be available on the EntreMed website
after each session.

Gynecologic Cancer Track: General Poster Session
Saturday, May 31, 2014 – 8:00AM – 11:45AM (CDT)
Abstract No.: TPS5620, Poster Board No.: 397B
Title: Phase II Study of Oral ENMD-2076 Administered to Patients with
Ovarian Clear Cell Carcinoma: A Trial of the Princess Margaret Phase
II Consortium
Location: S Hall A2

Sarcoma Track: Poster Highlight Session
Time 1:
Tuesday, June 3, 2014 – 8:00AM – 11:00AM (CDT)
Abstract No.: 10528, Poster Board No.: 16
Title: Phase II Study of Oral ENMD-2076 Administered to Patients
(pts) With Advanced Soft Tissue Sarcoma (STS)
Location: S102
Time 2:
Tuesday June 3, 2014 – 11:30 AM to 12:45 PM (CDT)
Location 2: S100bc